AttendMe Owl Logo
AttendMe
Evidence Evolution
Allergy & ImmunologyAllergy & Immunology

How This Evidence Evolved

Allergen Immunotherapy Modalities

From Subcutaneous Injections to Oral and Epicutaneous Delivery

1.4

Timeline

Signal

Early observations and pilot data that first suggested a new direction

Allergen immunotherapy began with Leonard Noon in 1911. SCIT is used for respiratory allergies and venom allergy, but requires repeated clinic injections over years. A 2014 review reported very severe systemic reactions at about 1 per million injections; this is not a fatality estimate. The EAACI user's guide describes weekly SCIT up-dosing followed by monthly maintenance for at least 3 years and poor completion. SLIT offers another route; its first tablet use was reported in 2001. A separate 5-year grass-tablet trial found symptom scores 25%-36% lower than placebo across five pollen seasons after 3 years of treatment and 2 years of blinded follow-up (P<=0.004). Food allergy also creates demand for allergen-specific treatments.
Proof

Landmark RCTs and pivotal trials that established the evidence base

A US trial of the 300IR 5-grass pollen sublingual tablet (473 adults) cut the daily combined symptom-medication score by 28.2% relative to placebo (mean difference -0.13; 95% CI -0.19 to -0.06; P=.0003), with no anaphylaxis. A postmarketing analysis evaluated FDA-approved SLIT tablets including Grastek, Ragwitek and Odactra. For food allergy, PALISADE found that 67.2% of peanut-allergic participants aged 4-17 receiving AR101 tolerated at least 600 mg of peanut protein without dose-limiting symptoms at the exit challenge, versus 4.0% with placebo (P<0.001). A regulatory review describes Palforzia's January 2020 FDA approval as the first approved food-allergy therapy.
Extension

Follow-up studies, subgroup analyses, and real-world validation

Epicutaneous immunotherapy delivers allergen through a skin patch. In the phase 3 PEPITES trial, 356 children aged 4-11 received a daily 250 ug peanut patch or placebo for 12 months: responder rates were 35.3% versus 13.6% (difference 21.7%; 95% CI 12.4%-29.8%; P<.001). The confidence interval's lower bound did not meet the prespecified 15% threshold for a positive trial. Treatment-emergent adverse events, mainly application-site reactions, occurred in 95.4% versus 89%; 10.5% versus 9.3% discontinued. Research approaches include hypoallergenic recombinant derivatives and T-cell peptides intended to bypass IgE binding, alongside new adjuvants intended to improve safety and efficacy. These approaches still require clinical evaluation.
Guidelines

Integration into clinical practice guidelines and recommendations

In the US 300IR grass-tablet trial, the most frequent adverse events were oral pruritus, throat irritation and nasopharyngitis; no anaphylaxis occurred and no actively treated participant used epinephrine. EAACI recommends product-specific evaluation of evidence and at least 3 years of treatment for long-term efficacy in allergic rhinoconjunctivitis. PALISADE reported adverse events in more than 95% of participants aged 4-17; severe events occurred in 4.3% with AR101 versus 0.8% with placebo. Participants completing the regimen received 300 mg daily maintenance for approximately 24 weeks before the exit challenge. Palforzia's approval does not remove the need to discuss treatment harms.
EAACI guideline on management of IgE-mediated food allergy
EAACI guideline on management of IgE-mediated food allergy
Now

Current standard of care and ongoing research directions

The immunotherapy landscape continues to develop. Research includes intralymphatic and epicutaneous delivery, modified allergens and combinations with biologics. Biomarker research includes allergen-specific IgE ratios, basophil activation testing and cellular markers; component-resolved diagnosis can inform treatment selection. Further studies must validate predictions of treatment response. The regulatory and clinical role of Viaskin Peanut remains a separate question.

Landmark Trials in This Story

Allergy 2009

Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009

Position paper on SLIT

Allergy
SQ grass tablet 5-year trial2012

SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.

Rhinoconjunctivitis daily symptom score over 5 grass pollen seasons (3 treatment years plus 2 follow-up years): 25% to 36% lower with SQ grass tablet vs placebo (P <= .004); weighted combined score 27% to 41% lower (P <= .003)

J Allergy Clin ImmunolDouble-blind, placebo-controlled, multinational phase III RCT; 3 years of SQ-standardized grass tablet or placebo, then 2 years of blinded follow-up (238 completers)
Current opinion in allergy and clinical immunology 2014

Anaphylaxis: still a ghost behind allergen immunotherapy.

Very severe SCIT systemic reaction rate in the reviewed surveillance data: approximately 1 per million injections

Current opinion in allergy and clinical immunologyReview
J Allergy Clin Immunol 2012Landmark

Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE

Combined symptom and medication score during grass season

J Allergy Clin ImmunolRCTN=473
PALISADE2018Landmark

AR101 Oral Immunotherapy for Peanut Allergy

Toleration of ≥600mg peanut protein at exit food challenge without dose-limiting symptoms

New England journal of medicineRCTN=551
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2020

Oral immunotherapy for treatment of peanut allergy.

January 2020 FDA approval of peanut oral immunotherapy; first approved food-allergy therapy

Journal of investigative medicine : the official publication of the American Federation for Clinical ResearchReview
Naunyn-Schmiedeberg's archives of pharmacology 2026

Post-marketing safety evaluation and objective benefit-risk assessment of sublingual immunotherapy tablets in allergic rhinitis.

Postmarketing safety analysis: 1509 suspected SLIT-tablet cases; 59.17% of reported adverse events non-serious

Naunyn-Schmiedeberg's archives of pharmacologyRetrospective pharmacovigilance analysis of FAERS reports from 2014-2025
PEPITES2019

Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.

Responder rate (eliciting-dose threshold) at month 12: 35.3% peanut patch vs 13.6% placebo (difference 21.7%; 95% CI 12.4%-29.8%; P < .001; prespecified 15% lower CI bound not met)

JAMAPhase 3, randomized, double-blind, placebo-controlled trial; daily 250 ug peanut patch vs placebo for 12 months in children aged 4-11N=356
Current opinion in allergy and clinical immunology 2014

Novel immunotherapy vaccine development.

Review of vaccine approaches, including hypoallergenic derivatives, peptides, adjuvants and administration routes

Current opinion in allergy and clinical immunologyReview
Pharmaceuticals (Basel, Switzerland) 2024

Novel Approaches to Allergen Immunotherapy for Respiratory Allergies.

Review of intralymphatic, epicutaneous, recombinant, peptide and biologic-combination approaches

Pharmaceuticals (Basel, Switzerland)Review
Chinese medical journal 2026

Recent advances in allergen immunotherapy.

Review of biomarkers and novel allergen vaccines; further predictive-biomarker research recommended

Chinese medical journalReview

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

How does sublingual immunotherapy compare to subcutaneous injections?+
SLIT tablets have allergen-specific trial evidence. In a US 300IR grass-tablet trial, the daily combined symptom-medication score fell 28.2% relative to placebo (P=.0003); frequent adverse events included oral pruritus, throat irritation and nasopharyngitis, and no anaphylaxis occurred. EAACI's user's guide recommends observing the first SLIT dose in clinic for at least 30 minutes; later doses usually occur outside the clinic. SCIT requires clinic administration. Route and product selection require individual assessment.
Is peanut oral immunotherapy a cure for peanut allergy?+
PALISADE demonstrated desensitization: a higher peanut-protein reaction threshold at the exit food challenge. Participants completing the regimen took 300 mg daily for approximately 24 weeks of maintenance before that challenge. The trial did not test tolerance after treatment stopped or protection during accidental exposures. A regulatory review notes that oral immunotherapy does not lead to sustained unresponsiveness and that side effects and long-term risks require attention.
What are the risks of food allergy oral immunotherapy?+
In PALISADE, adverse events during the intervention period affected more than 95% of participants aged 4-17. In the AR101 group, 34.7% had mild events, 59.7% moderate events, and 4.3% severe events, compared with 50.0%, 44.4%, and 0.8% with placebo. At the exit food challenge, the maximum symptom severity was moderate in 25% of the AR101 group vs 59% with placebo, and severe in 5% vs 11%.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026